- Home
- FFA vs ANGO Comparison
FFA vs ANGO Comparison
Compare FFA & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFA
- ANGO
- Stock Information
- Founded
- FFA 2004
- ANGO 1988
- Country
- FFA United States
- ANGO United States
- Employees
- FFA N/A
- ANGO N/A
- Industry
- FFA Investment Managers
- ANGO Medical/Dental Instruments
- Sector
- FFA Finance
- ANGO Health Care
- Exchange
- FFA Nasdaq
- ANGO Nasdaq
- Market Cap
- FFA 400.0M
- ANGO 439.5M
- IPO Year
- FFA N/A
- ANGO 2004
- Fundamental
- Price
- FFA $19.13
- ANGO $9.11
- Analyst Decision
- FFA
- ANGO Strong Buy
- Analyst Count
- FFA 0
- ANGO 2
- Target Price
- FFA N/A
- ANGO $14.00
- AVG Volume (30 Days)
- FFA 26.1K
- ANGO 330.9K
- Earning Date
- FFA 01-01-0001
- ANGO 04-02-2025
- Dividend Yield
- FFA 6.72%
- ANGO N/A
- EPS Growth
- FFA N/A
- ANGO N/A
- EPS
- FFA N/A
- ANGO N/A
- Revenue
- FFA N/A
- ANGO $283,320,000.00
- Revenue This Year
- FFA N/A
- ANGO N/A
- Revenue Next Year
- FFA N/A
- ANGO $6.35
- P/E Ratio
- FFA N/A
- ANGO N/A
- Revenue Growth
- FFA N/A
- ANGO N/A
- 52 Week Low
- FFA $15.84
- ANGO $5.47
- 52 Week High
- FFA $19.30
- ANGO $13.50
- Technical
- Relative Strength Index (RSI)
- FFA 55.83
- ANGO 46.41
- Support Level
- FFA $18.93
- ANGO $8.55
- Resistance Level
- FFA $19.40
- ANGO $9.68
- Average True Range (ATR)
- FFA 0.27
- ANGO 0.36
- MACD
- FFA 0.13
- ANGO -0.02
- Stochastic Oscillator
- FFA 83.89
- ANGO 46.28
About FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide a high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.